ESMO TAT 2021 | The impact of COVID-19 on validating cell therapy products

Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses the impact of COVID-19 on validating cell therapy products. Despite mesenchymal stromal cells having been established as a cell-based therapy for acute respiratory distress syndrome (ARDS), they have yet to be specifically utilized in viral respiratory infections. Dr. Levine also evaluates the recent influx of research on this topic, urging caution as well as stressing patient safety and scientific rationale when creating new proposals. This interview took place during the ESMO TAT 2021 conference.